2022
Can transfusion-associated graft-versus-host disease (TA-GvHD) be prevented with leukoreduction alone?
Rodriguez JV, Tormey CA. Can transfusion-associated graft-versus-host disease (TA-GvHD) be prevented with leukoreduction alone? Transfusion And Apheresis Science 2022, 61: 103402. PMID: 35288056, DOI: 10.1016/j.transci.2022.103402.Peer-Reviewed Original ResearchConceptsTransfusion-associated graftTA-GVHDHost diseaseCellular blood productsHigh mortality rateWhite blood cellsBlood productsEffective treatmentMortality rateTransfusion communityHigh mortalityMedical literatureBlood cellsDiseaseDevastating diseaseGraftLeukocytesLeukoreductionQuantitative reductionHospitalMortality
2020
Preventing transfusion‐associated graft‐versus‐host disease with blood component irradiation: indispensable guidance for a deadly disorder
Loingsigh S, Flegel WA, Hendrickson JE, Tormey CA. Preventing transfusion‐associated graft‐versus‐host disease with blood component irradiation: indispensable guidance for a deadly disorder. British Journal Of Haematology 2020, 191: 653-657. PMID: 32738068, PMCID: PMC9128360, DOI: 10.1111/bjh.17016.Peer-Reviewed Original ResearchConceptsTransfusion-associated graftHost diseaseDeadly disorderBlood component irradiationComponent irradiationGraftDisease
2018
Prevention of Transfusion-Associated Graft-Versus-Host Disease With Blood Product Irradiation: The Past, Present, and Future
Bahar B, Tormey CA. Prevention of Transfusion-Associated Graft-Versus-Host Disease With Blood Product Irradiation: The Past, Present, and Future. Archives Of Pathology & Laboratory Medicine 2018, 142: 662-667. PMID: 29684286, DOI: 10.5858/arpa.2016-0620-rs.Peer-Reviewed Original Research